Author:
Touboul Cyril,Vidal Fabien,Pasquier Jennifer,Lis Raphael,Rafii Arash
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference162 articles.
1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62: 10-29.
2. Leminen A, Auranen A, Butzow R, Hietanen S, Komulainen M, Kuoppala T, Maenpaa J, Puistola U, Vuento M, Vuorela P, Yliskoski M: Update on current care guidelines: ovarian cancer. Duodeciml. 2012, 128: 1300-1301.
3. Stehman FB, Brady MF, Thigpen JT, Rossi EC, Burger RA: Cytokine use and survival in the first-line treatment of ovarian cancer: A Gynecologic Oncology Group Study. Gynecol Oncol. 2012, 127 (3): 495-501.
4. Mobus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, Ostermann H, Hinke A, Ledermann JA: Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol. 2007, 25: 4187-4193.
5. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003, 21: 283-290.
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献